Beam Therapeutics’ first clinical data in the rare disease alpha-1 antitrypsin deficiency “set a bar for efficacy in the space,” according to one analyst. But the ongoing market slide poses challenges for biotech companies aiming to raise money by selling stock.
The post Beam Base Editor’s Early Data in Rare Liver Disease Tee Up $500M Stock Sale in Tough Market appeared first on MedCity News.
